Navigating the Expanding Treatment Landscape in Metastatic Urothelial Cancer: Novel Targeted Therapies
If you claimed credit for the live session during JADPRO LIVE, you are not eligible to claim credit for this enduring.
Petros Grivas, MD, PhD
Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
University of Washington School of Medicine
Clinical Director, Genitourinary Cancers Program
University of Washington Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Nerina T. McDonald, PA-C
Seattle Cancer Care Alliance
University of Washington Medicine
Provided by North American Center for Continuing Medical Education, LLC (NACCME), an HMP Global Company.
For questions regarding this educational activity, please call 609-371-1137 or email firstname.lastname@example.org.
This activity is designed for advanced practitioners, including nurse practitioners (NPs), physician assistants (PAs), clinical nurse specialists, advanced degree nurses, and pharmacists.
After participating in this activity, learners should be better able to:
- Assess evidence-based guidelines and recent safety and efficacy data of first-line, second-line, and subsequent-line therapies for the treatment of mUC
- Evaluate the profiles of antibody-drug conjugates for the treatment of mUC, including mechanisms of action, efficacy, safety, and potential treatment benefits
- Apply strategies to appropriately utilize antibody-drug candidates in clinical practice for the treatment of mUC according to current guideline recommendations
- Implement patient-centered care and education strategies to address treatment barriers, adverse events, and healthcare disparities in mUC
To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.
Release Date: October 18, 2021
Expiration Date: Deember 31, 2022
Estimated Time to Complete: 1.25 hour
There is no fee associated with this activity.
NACCME would like to thank the following company who has supported "Navigating the Expanding Treatment Landscape in Metastatic Urothelial Cancer: Novel Targeted Therapies" through educational grants and/or in-kind support: Astellas and Seagen Inc.
In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NACCME designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing nursing education enduring activity awards 1.25 contact hours.
Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.25 contact hours.
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.
This internet enduring, knowledge-based activity (Universal Activity Number:JA0006201-0000-21-179-H01-P) has been approved for a maximum of 1.25 contact hours (1.25 CEUs).
The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, NACCME must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. NACCME is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.
NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This enduring activity is designated for 1.25 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
USE OF PROPRIETARY NAMES
This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.
UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.
The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.
The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
NACCME, LLC is an independent provider of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.
In accordance with our disclosure policies, NACCME is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.
Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:
- Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
- Any investigational, off-label, or non-FDA approved content or discussion
NACCME has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.
Education has been independently peer-reviewed to validate content, mitigate identified conflicts of interest, and ensure:
- All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
- All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
- Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.
The faculty has reported the following:
Dr. Grivas: Institutional Research Funding – Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, EMD Serono, Immunomedics/Gilead, Pfizer, Merck, QED Therapeutics, GlaxoSmithKline, Mirati Therapeutics; Consulting – AstraZeneca, Astellas Pharma, Bristol Myers Squibb, Dyania Health, EMD Serono, Exelixis, Immunomedics/Gilead, Infinity Pharmaceuticals, Janssen, Merck, Mirati Therapeutics, Genentech/Roche, Guardant Health, Pfizer, QED Therapeutics, Regeneron Pharmaceuticals, Seagen, 4D Pharma PLC
Ms. McDonald has disclosed no relevant financial relationship with any ineligible company (commercial interest).
Tara L. Lin, MD
Division of Hematologic Malignancies and Cellular Therapeutics
University of Kansas Cancer Center
Kansas City, Kansas
Dr. Lin has disclosed no relevant financial relationship with any ineligible company (commercial interest).
Susie Seaman, NP, MSN, CWOCN (nurse planner)
Susie Seaman Wound Care Consulting
San Diego, CA
Ms. Seaman has disclosed no relevant financial relationship with any ineligible company (commercial interest).
NACCME planners and staff include Samantha Conforti, Melissa Merz, Paul O'Neil, Randy Robbin, Greaton Sellers, Margie Stefan and Joanna Tong.
No NACCME planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).
North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2021 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.
Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at email@example.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Conforti will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Associate Director, Greaton Sellers, Accreditation and Compliance, can be requested for a second level of review. Mr. Sellers can be contacted via phone at 609-371-1137, by email at firstname.lastname@example.org or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520.